- Switzerland
- /
- Medical Equipment
- /
- SWX:SOON
An Intrinsic Calculation For Sonova Holding AG (VTX:SOON) Suggests It's 24% Undervalued
Key Insights
- Using the 2 Stage Free Cash Flow to Equity, Sonova Holding fair value estimate is CHF303
- Current share price of CHF231 suggests Sonova Holding is potentially 24% undervalued
- Analyst price target for SOON is CHF254 which is 16% below our fair value estimate
Does the August share price for Sonova Holding AG (VTX:SOON) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.
We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
See our latest analysis for Sonova Holding
The Calculation
We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To start off with, we need to estimate the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
Generally we assume that a dollar today is more valuable than a dollar in the future, so we need to discount the sum of these future cash flows to arrive at a present value estimate:
10-year free cash flow (FCF) estimate
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (CHF, Millions) | CHF637.8m | CHF755.7m | CHF829.7m | CHF882.5m | CHF879.5m | CHF877.6m | CHF876.3m | CHF875.5m | CHF874.9m | CHF874.5m |
Growth Rate Estimate Source | Analyst x7 | Analyst x8 | Analyst x7 | Analyst x5 | Analyst x3 | Est @ -0.21% | Est @ -0.15% | Est @ -0.10% | Est @ -0.07% | Est @ -0.04% |
Present Value (CHF, Millions) Discounted @ 4.8% | CHF609 | CHF689 | CHF722 | CHF733 | CHF697 | CHF664 | CHF633 | CHF604 | CHF576 | CHF550 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CHF6.5b
After calculating the present value of future cash flows in the initial 10-year period, we need to calculate the Terminal Value, which accounts for all future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 0.01%. We discount the terminal cash flows to today's value at a cost of equity of 4.8%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = CHF875m× (1 + 0.01%) ÷ (4.8%– 0.01%) = CHF18b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CHF18b÷ ( 1 + 4.8%)10= CHF12b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CHF18b. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of CHF231, the company appears a touch undervalued at a 24% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
Important Assumptions
Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Sonova Holding as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 4.8%, which is based on a levered beta of 0.949. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Sonova Holding
- Debt is well covered by earnings and cashflows.
- Dividends are covered by earnings and cash flows.
- Earnings declined over the past year.
- Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
- Annual revenue is forecast to grow faster than the Swiss market.
- Good value based on P/E ratio and estimated fair value.
- Annual earnings are forecast to grow slower than the Swiss market.
Next Steps:
Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. What is the reason for the share price sitting below the intrinsic value? For Sonova Holding, there are three pertinent factors you should assess:
- Risks: Case in point, we've spotted 2 warning signs for Sonova Holding you should be aware of.
- Future Earnings: How does SOON's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!
PS. Simply Wall St updates its DCF calculation for every Swiss stock every day, so if you want to find the intrinsic value of any other stock just search here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SWX:SOON
Sonova Holding
Manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific.
Fair value with moderate growth potential.